Specialistkliniken för Oral Protetik, SU/Mölndal, 431 80 Mölndal, Sweden.
Clin Implant Dent Relat Res. 2012 Aug;14(4):471-9. doi: 10.1111/j.1708-8208.2010.00290.x. Epub 2010 Jun 25.
Knowledge on long-term clinical performance of more than 5 years on the single-implant CeraOne™ (Nobel Biocare AB, Gothenburg, Sweden) concept is limited.
The aim of this study is to report the long-term clinical performance of the first CeraOne single-implant restorations, installed 17 to 19 years ago.
The group comprised 57 patients provided with 65 CeraOne single-tooth restorations. Sixty-two all-ceramic and three metal-ceramic crowns were cemented between 1989 and 1991. Patients were followed up clinically and with intraoral radiographs at placement, after 1, 5, and between 17 and 19 years after placement.
Data were available for altogether 48 patients, followed up on an average time of 18 years. Excluding deceased patients (n=2) and failed implant patients (n=2), only five patients were lost to follow-up (8.8%). Two implants failed, resulting in an 18-year implant cumulative success rate (CSR) of 96.8%, and altogether eight original single-crown restorations were replaced (CSR 83.8%). The most common reason for crown replacement was infra-position of the implant crown (n=3). Many of the remaining original crowns showed various signs of implant crown infraposition at the termination of the study. In general, the soft tissue at the restorations was assessed to be healthy and comparable with the gingiva at the adjacent natural teeth. Bone levels were on an average stable with only few patients exhibiting bone loss of more than 2mm during 18 years in function.
This long-term follow-up study of single-implant restorations shows encouraging results with few implant failures and minimal bone loss over an 18-year period. Original single-crown restorations were replaced more frequently, because of, for example, implant crown infraposition and veneer fractures. The CeraOne concept proved to be a highly predictable and safe prosthodontic treatment.
关于 CeraOne™(瑞典哥德堡诺贝尔生物公司)单种植体概念超过 5 年的长期临床性能知之甚少。
本研究旨在报告首例 CeraOne 单种植体修复体的长期临床性能,这些修复体于 17 至 19 年前安装。
该组包括 57 名患者,共植入 65 个 CeraOne 单牙修复体。62 个全瓷和 3 个金属-陶瓷冠于 1989 年至 1991 年间粘结。患者在植入时、植入后 1 年、5 年以及植入后 17 至 19 年进行临床和口腔内射线检查随访。
共有 48 名患者的数据可用于平均 18 年的随访。排除死亡患者(n=2)和失败种植体患者(n=2),仅有 5 名患者失访(8.8%)。2 个种植体失败,18 年种植体累积成功率(CSR)为 96.8%,共有 8 个原始单冠修复体被更换(CSR 83.8%)。冠修复体更换的最常见原因是种植体冠位置过低(n=3)。在研究结束时,许多剩余的原始冠显示出各种种植体冠位置过低的迹象。总的来说,修复体的软组织被评估为健康的,与相邻天然牙的牙龈相当。骨质水平总体稳定,只有少数患者在 18 年的功能中出现超过 2mm 的骨质流失。
这项单种植体修复体的长期随访研究显示,种植体失败率低,骨质丢失少,18 年期间效果令人鼓舞。原始单冠修复体更换更为频繁,原因包括种植体冠位置过低和贴面破裂等。CeraOne 概念被证明是一种高度可预测和安全的修复治疗方法。